Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications

References

• Garrido-Mesa N, Zarzuelo A, Gálvez J. What is behind the non-antibiotic properties of minocycline? Pharmacol Res. 2013;67(1):18–30.
   PubMed Web of Science ®Google Scholar
• Fuoco D. Classification framework and chemical biology of tetracycline-structure-based drugs. Antibiot Basel Switz. 2012;1:1–13.
   PubMedGoogle Scholar
• Garrido-Mesa N, Zarzuelo A, Gálvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol. 2013;169(2):337–352.
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. Internet]. 2020 cited 2021 Mar 25;395:507–513. Available from;10223: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30211-7/abstract
   PubMed Web of Science ®Google Scholar
• Bussani R, Schneider E, Zentilin L, et al. Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology. EBioMedicine. 2020;61:103104.
   PubMed Web of Science ®Google Scholar
• Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–848.
   PubMed Web of Science ®Google Scholar
• Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. Internet]. 2020 cited 2021 Feb 22;10:766–788. Available from;5: https://www.sciencedirect.com/science/article/pii/S2211383520302999
   PubMed Web of Science ®Google Scholar
• Sayed AM, Khalaf AM, Abdelrahim MEA, et al. Repurposing of some anti-infective drugs for COVID-19 treatment: a surveillance study supported by an in silico investigation. Int J Clin Pract. 2020;75(4):e13877.
   PubMed Web of Science ®Google Scholar
• Putics Á, Filipowicz W, Hall J, et al. ADP-Ribose-1”-monophosphatase: a conserved coronavirus enzyme that is dispensable for viral replication in tissue culture. J Virol. Internet]. 2005 cited 2021 Jul 4;79:12721–12731. Available from;20: https://journals.asm.org/doi/full/10.1128/JVI.79.20.12721-12731.2005
   PubMed Web of Science ®Google Scholar
• Sachdeva C, Wadhwa A, Kumari A, et al. In silicoPotential of approved antimalarial drugs for repurposing against COVID-19. Omics J Integr Biol. 2020;24(10):568–580.
   PubMed Web of Science ®Google Scholar
• Zhao TY, Patankar NA. Tetracycline as an inhibitor to the coronavirus SARS-CoV-2. J Cell Biochem [Internet]. 2021 [cited 2021 Mar 15];jcb.29909. Available from: http://arxiv.org/abs/2008.06034.
   Web of Science ®Google Scholar
• Bharadwaj S, Lee KE, Dwivedi VD, et al. Computational insights into tetracyclines as inhibitors against SARS-CoV-2 Mpro via combinatorial molecular simulation calculations. Life Sci. 2020;257:118080.
   PubMed Web of Science ®Google Scholar
• Gendrot M, Andreani J, Jardot P, et al. In vitro antiviral activity of doxycycline against SARS-CoV-2. 2020;25(21):5064. https://doi.org/https://doi.org/10.3390/molecules25215064
   Google Scholar
• Yang J, Petitjean SJL, Koehler M, et al. Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor. Nat Commun. Internet]. 2020 cited 2021 Oct 22;11:4541. Available from;1: https://www.nature.com/articles/s41467-020-18319-6
   PubMed Web of Science ®Google Scholar
• Diomede L, Baroni S, De Luigi A, et al. Doxycycline inhibition of a pseudotyped virus transduction does not translate to inhibition of SARS-CoV-2 infectivity. Viruses. 2021;13(9):1745.
   PubMed Web of Science ®Google Scholar
• Tummino TA, Rezelj VV, Fischer B, et al. Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2. Science. Internet]. 2021 cited 2021 Oct 20;373:541–547. Available from;6554: https://www.science.org/doi/full/10.1126/science.abi4708
   PubMed Web of Science ®Google Scholar
• Szolnoky G. Further aspects of doxycycline therapy in COVID-19. Dermatol Ther [Internet]. 2020 cited 2021 Feb 22;33:e13810. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/dth.13810.
   PubMed Web of Science ®Google Scholar
• Zink MC, Uhrlaub J, DeWitt J, et al. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA. 2005;293(16):2003–2011.
   PubMed Web of Science ®Google Scholar
• Rothan HA, Mohamed Z, Paydar M, et al. Inhibitory effect of doxycycline against dengue virus replication in vitro. Arch Virol. 2014;159(4):711–718.
   PubMed Web of Science ®Google Scholar
• Mishra MK, Basu A. Minocycline neuroprotects, reduces microglial activation, inhibits caspase 3 induction, and viral replication following Japanese encephalitis. J Neurochem. Internet]. 2008 cited 2021 Mar 15;105:1582–1595. Available from.;(5):. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1471-4159.2008.05238.x
   PubMed Web of Science ®Google Scholar
• Topno R, Khan SA, Chowdhury P, et al. Pharmacodynamics of aminoglycosides and tetracycline derivatives against Japanese encephalitis virus. Asian Pac J Trop Med. 2016;9(3):241–246.
   PubMed Web of Science ®Google Scholar
• Dutta K, Basu A. Use of minocycline in viral infections. Indian J Med Res. 2011;133:467–470.
   PubMed Web of Science ®Google Scholar
• Ding S-W, Voinnet O. Antiviral immunity directed by small RNAs. Cell. 2007;130(3):413–426.
   PubMed Web of Science ®Google Scholar
• Szeto GL, Brice AK, Yang H-C, et al. Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4 + T cells. J Infect Dis. 2010;201(8):1132–1140.
   PubMed Web of Science ®Google Scholar
• Garcia-Martinez EM, Sanz-Blasco S, Karachitos A, et al. Mitochondria and calcium flux as targets of neuroprotection caused by minocycline in cerebellar granule cells. Biochem Pharmacol. 2010;79(2):239–250.
   PubMed Web of Science ®Google Scholar
• Raza M, Ballering JG, Hayden JM, et al. Doxycycline decreases monocyte chemoattractant protein-1 in human lung epithelial cells. Exp Lung Res. 2006;32(1–2):15–26.
   PubMed Web of Science ®Google Scholar
• Hoyt JC, Ballering J, Numanami H, et al. Doxycycline modulates nitric oxide production in murine lung epithelial cells. J Immunol Baltim Md. 2006;176:567–572.
   PubMed Web of Science ®Google Scholar
• Moon A, Gil S, Gill SE, et al. Doxycycline impairs neutrophil migration to the airspaces of the lung in mice exposed to intratracheal lipopolysaccharide. J Inflamm Lond Engl. 2012;9(1):31.
   PubMedGoogle Scholar
• . Herath SC, Normansell R, Maisey S, et al. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2018; 10. CD009764 https://doi.org/10.1002/14651858.CD009764.pub3
   Google Scholar
• Maisi P, Kiili M, Raulo SM, et al. MMP inhibition by chemically modified tetracycline-3 (CMT-3) in equine pulmonary epithelial lining fluid. Ann N Y Acad Sci. Internet]. 1999 cited 2021 Mar 15;878:675–677. Available from;1 INHIBITION OF: https://nyaspubs.onlinelibrary.wiley.com/doi/abs/10.1111/j.1749-6632.1999.tb07759.x
   PubMedGoogle Scholar
• Peukert K, Fox M, Schulz S, et al. Inhibition of caspase-1 with tetracycline ameliorates acute lung injury. Am J Respir Crit Care Med. 2021;204(1):53–63.
   PubMed Web of Science ®Google Scholar
• Roy SK, Kendrick D, Sadowitz BD, et al. Jack of all trades: pleiotropy and the application of chemically modified tetracycline-3 in sepsis and the acute respiratory distress syndrome (ARDS). Pharmacol Res. Internet]. 2011 cited 2021 Mar 15;64:580–589. Available from;6: https://www.sciencedirect.com/science/article/pii/S1043661811001897
   PubMed Web of Science ®Google Scholar
• Steinberg J, Halter J, Schiller HJ, et al. Metalloproteinase inhibition reduces lung injury and improves survival after cecal ligation and puncture in rats. J Surg Res. Internet]. 2003 cited 2021 Mar 15;111:185–195. Available from;2: https://www.sciencedirect.com/science/article/pii/S0022480403000891
   PubMed Web of Science ®Google Scholar
• Steinberg J, Halter J, Schiller H, et al. Chemically modified tetracycline prevents the development of septic shock and acute respiratory distress syndrome in a clinically applicable porcine model. Shock Augusta Ga. 2005;24(4):348–356.
   PubMed Web of Science ®Google Scholar
• Carney David E, Lutz Charles J, Picone Anthony L, et al. Matrix metalloproteinase inhibitor prevents acute lung injury after cardiopulmonary bypass. Circulation. Internet]. 1999 cited 2021 Mar 15;100:400–406. Available from;4: https://www.ahajournals.org/doi/10.1161/01.CIR.100.4.400
   PubMed Web of Science ®Google Scholar
• McCann UG, Gatto LA, Searles B, et al. Matrix metalloproteinase inhibitor: differential effects on pulmonary neutrophil and monocyte sequestration following cardiopulmonary bypass. J Extra Corpor Technol. 1999;31(2):67–75.
   PubMedGoogle Scholar
• Halter JM, Pavone LA, Steinberg JM, et al. Chemically modified tetracycline (COL-3) improves survival if given 12 but not 24 hours after cecal ligation and puncture. Shock Augusta Ga. 2006;26(6):587–591.
   PubMed Web of Science ®Google Scholar
• Roy SK, Kubiak BD, Albert SP, et al. Chemically modified tetracycline 3 prevents acute respiratory distress syndrome in a porcine model of sepsis + ischemia/reperfusion–induced lung injury. Shock. Internet]. 2012 cited 2021 Mar 15;37:424–432. Available from;4: https://journals.lww.com/shockjournal/Fulltext/2012/04000/Chemically_Modified_Tetracycline_3_Prevents_Acute.13.aspx
   PubMed Web of Science ®Google Scholar
• Sadowsky D, Nieman G, Barclay D, et al. Impact of chemically-modified tetracycline 3 on intertwined physiological, biochemical, and inflammatory networks in porcine sepsis/ARDS. Int J Burns Trauma Internet]. 2015 cited 2021 Mar 15;5:22–35. Available from.;:. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4448085/
   PubMed Web of Science ®Google Scholar
• Kim JH, Suk MH, Yoon DW, et al. Inhibition of matrix metalloproteinase-9 prevents neutrophilic inflammation in ventilator-induced lung injury. Am J Physiol-Lung Cell Mol Physiol. Internet]. 2006 cited 2021 Mar 15;291:L580–L587. Available from;4: https://journals.physiology.org/doi/full/10.1152/ajplung.00270.2005
   PubMed Web of Science ®Google Scholar
• Zhou X, Wang D, Ballard-Croft CK, et al. A tetracycline analog improves acute respiratory distress syndrome survival in an ovine model. Ann Thorac Surg. Internet]. 2010 cited 2021 Mar 15;90:419–426. Available from;2: https://www.sciencedirect.com/science/article/pii/S0003497510009185
   PubMed Web of Science ®Google Scholar
• Yoshida S, Iwata T, Chiyo M, et al. Metalloproteinase inhibition has differential effects on alloimmunity, autoimmunity, and histopathology in the transplanted lung. Transplantation Internet]. 2007 cited 2021 Mar 15;83:799–808. Available from.;:. https://journals.lww.com/transplantjournal/Fulltext/2007/03270/Metalloproteinase_Inhibition_Has_Differential.23.aspx
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee SY, Bak SM, et al. Effects of matrix metalloproteinase inhibitor on LPS-induced goblet cell metaplasia. Am J Physiol - Lung Cell Mol Physiol. Internet]. 2004 cited 2021 Mar 15;287:L127–L133. Available from;1: https://koreauniv.pure.elsevier.com/en/publications/effects-of-matrix-metalloproteinase-inhibitor-on-lps-induced-gobl
   PubMed Web of Science ®Google Scholar
• He B, Garmire L. Prediction of repurposed drugs for treating lung injury in COVID-19. F1000Research [Internet]. 2020 cited 2021 Jul 4;9:609. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468567/.
   PubMedGoogle Scholar
• Ong CT, Babalola CP, Nightingale CH, et al. Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs). J Antimicrob Chemother. 2005;56(3):498–501.
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Gotfried MH, Cwik M, et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother. 2006;58(6):1221–1229.
   PubMed Web of Science ®Google Scholar
• Yates PA, Newman SA, Oshry LJ, et al. Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease. Ther Adv Respir Dis. 2020;14:1753466620951053.
   Web of Science ®Google Scholar
• Gironi LC, Damiani G, Zavattaro E, et al. Tetracyclines in COVID-19 patients quarantined at home: literature evidence supporting real-world data from a multicenter observational study targeting inflammatory and infectious dermatoses. Dermatol Ther. 2021 Jan;34(1):e14694. https://doi.org/https://doi.org/10.1111/dth.14694
   PubMed Web of Science ®Google Scholar
• Alam MM, Mahmud S, Rahman MM, et al. Clinical outcomes of early treatment with doxycycline for 89 high-risk COVID-19 patients in long-term care facilities in New York. Cureus. 2020;12(8):e9658.
   PubMed Web of Science ®Google Scholar
• Cag Y, Icten S, Isik-Goren B, et al. A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2021;40(2):407–411.
   PubMed Web of Science ®Google Scholar
• Hashim HA, Maulood MF, Rasheed AM, et al. Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq [Internet]. Infec Dis (except HIV/AIDS); 2020 cited 2021 Mar 15]. Available from 2021 Mar 15: http://medrxiv.org/lookup/doi/10.1101/2020.10.26.20219345.
   Google Scholar
• Mahmud R, Rahman MM, Alam I, et al. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial. J Int Med Res. 2021;49(5):3000605211013550.
   Web of Science ®Google Scholar
• Butler CC, L-M Y, Dorward J, et al. Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet Respir Med. 2021;9(9):1010–1020.
   PubMed Web of Science ®Google Scholar
• Bonjoch L, Gea-Sorlí S, Jordan J, et al. Minocycline inhibits peritoneal macrophages but activates alveolar macrophages in acute pancreatitis. J Physiol Biochem. 2015;71(4):839–846.
   PubMed Web of Science ®Google Scholar
• Dunston CR, Griffiths HR, Lambert PA, et al. Proteomic analysis of the anti-inflammatory action of minocycline. Proteomics. 2011;11(1):42–51.
   PubMed Web of Science ®Google Scholar
• Garrido-Mesa J, Rodríguez-Nogales A, Algieri F, et al. Immunomodulatory tetracyclines shape the intestinal inflammatory response inducing mucosal healing and resolution. Br J Pharmacol. 2018;175(23):4353–4370.
   PubMed Web of Science ®Google Scholar
• Garrido-Mesa J, Algieri F, Rodríguez-Nogales A, et al. Immunomodulatory tetracyclines ameliorate DNBS-colitis: impact on microRNA expression and microbiota composition. Biochem Pharmacol. 2018;155:524–536.
   PubMed Web of Science ®Google Scholar